Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
Lupron
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to lupron in premenopausal women with early breast cancer?
Related Questions
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
What are your top takeaways in Breast Cancer from ESMO 2024?
How would you approach treatment for local chest wall recurrence while on Anastrozole for a postmenopausal woman with ER+ IDC s/p mastectomy?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines? If so, how often do you check?
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
What modifications, if any, will you make for your use of dose dense taxane chemotherapy in early stage breast cancer with the end-of-study PANTHER results?
